Authorised Therapeutic exploratory (Phase II) Refractory Metastatic Breast Cancer with Liver Dominant Disease

Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer

EU CTIS ID: 2025-521966-91-00

What this study is testing

To evaluate the effect of Melphalan/HDS followed by physicians’ choice of eribulin or vinorelbine or capecitabine on hepatic progression free survival (hPFS) compared to that of eribulin or vinorelbine or capecitabine alone in patients with liver dominant metastatic breast cancer (MBC).

  • Therapeutic exploratory (Phase II)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • Patient is ≥ 18 years of age on day of consent
  • If there is evidence of extrahepatic metastatic disease, it is limited, and the life-threatening component of disease is in the liver. Extrahepatic disease is restricted to lesions in the breast, lung, other visceral organs, lymph nodes, bones and skin
  • Each extrahepatic lesion must not exceed 3 cm in diameter and the total diameter of all extrahepatic lesions must not exceed 20 cm. Additionally, the maximum diameter of tumor lesions within each specific organ cannot be greater than 5 cm. Bone disease is allowed but is excluded from the extrahepatic tumor burden threshold
  • Disease in the liver must be measurable (per RECIST v1.1 guidelines) by computed tomography (CT) and/or magnetic resonance imaging (MRI)
  • Patient weighs ≥ 35 kg (due to possible size limitations with respect to percutaneous catheterization of the femoral artery and vein required with Melphalan/HDS)
  • Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and MRI of the liver) must be performed within 28 days prior to randomization

You likely can't join if

  • Prior chemoembolization or radioembolization to the liver or prior hepatic arterial infusion therapy.
  • Patient is a WOCBP (i.e., fertile meaning not permanently sterilized and having had a menstrual period within the past 12 months) who is unable to undergo hormonal suppression to avoid menstruation during treatment.
  • Patient requires chronic use of immunosuppressive drugs. NOTE: Oral prednisolone ≤ 10 mg/day or equivalent is allowed.
  • Patient is unable to be temporarily removed from chronic anti-coagulation therapy.
  • Patient has active bacterial infections with systemic manifestations (malaise, fever, leukocytosis).
  • Patient has an active infection, including Hepatitis B and Hepatitis C infection. NOTE: Patients with anti-hepatitis B core antibody (HBc) positive, or hepatitis B surface antigen (HBsAg) but DNA negative are allowed exception(s).
See the full eligibility criteria
Who can join
  • Patient is ≥ 18 years of age on day of consent
  • If there is evidence of extrahepatic metastatic disease, it is limited, and the life-threatening component of disease is in the liver. Extrahepatic disease is restricted to lesions in the breast, lung, other visceral organs, lymph nodes, bones and skin
  • Each extrahepatic lesion must not exceed 3 cm in diameter and the total diameter of all extrahepatic lesions must not exceed 20 cm. Additionally, the maximum diameter of tumor lesions within each specific organ cannot be greater than 5 cm. Bone disease is allowed but is excluded from the extrahepatic tumor burden threshold
  • Disease in the liver must be measurable (per RECIST v1.1 guidelines) by computed tomography (CT) and/or magnetic resonance imaging (MRI)
  • Patient weighs ≥ 35 kg (due to possible size limitations with respect to percutaneous catheterization of the femoral artery and vein required with Melphalan/HDS)
  • Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and MRI of the liver) must be performed within 28 days prior to randomization
  • Patient has an ECOG PS of 0-1
  • Patient has adequate hepatic function documented within 14 days prior to randomization: total serum bilirubin ≤1.5 x the upper limit of normal (ULN), prothrombin time (PT) within 2 seconds of the ULN, and aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 5 x ULN. Patient with a documented diagnosis of Gilbert’s syndrome may be eligible with total bilirubin ≤ 3.0 × ULN and direct (conjugated) bilirubin ≤ 1.5 × ULN
  • Patient has the following documented within 14 days prior to randomization: platelet count > 100,000/μL; hemoglobin ≥ 9 gm/dL; white blood cell count (WBC) > 2,000/ μL; absolute neutrophil count ≥ 1.5 x 109/L; and creatinine clearance > 50 mL/min/ (as determined by the Cockcroft-Gault formula)
  • Woman of childbearing potential (WOCBP) (i.e., fertile meaning not permanently sterilized and having had a menstrual period within the past 12 months), should have a negative serum pregnancy test (β-human chorionic gonadotropin) within 7 days prior to randomization
  • If patient is a WOCBP or fertile male (not permanently sterile by bilateral orchiectomy), they or their partner must be willing to use a highly effective contraception method (e.g., combined hormonal contraception; progestogenonly hormonal contraception; intrauterine device, intrauterine hormonereleasing system; bilateral tubal occlusion, vasectomized partner or sexual abstinence) from consent to at least 6 months after the last administration of study treatment. Additionally, WOCBP using hormonal contraception must be willing to add a barrier contraception method, and fertile males must be willing to use a condom
  • Histologically confirmed diagnosis of MBC
  • Signed informed consent
  • Patients with HER2-negative (IHC 0 or 1+ or 2+ and ISH non-amplified) MBC (including triple negative disease)
  • Patient with Hormone Receptor-Positive disease has progressed on or intolerant of prior endocrine therapy and CDK 4/6 inhibitors
  • Disease progression after TOPO-1 isomerase inhibitor payload ADC, such as sacituzumab govitecan and/or trastuzumab deruxtecan. Patients not eligible or suitable for ADCs can be considered for this study. NOTE: In jurisdictions where those ADCs are not available as standard of care, patients will be eligible after prior treatment or intolerable toxicity on two standard chemotherapy regimens for the appropriate disease subtype
  • Patient with HER2-negative breast cancer suitable for single agent chemotherapy as per judgement of treating investigator
  • Patient is a suitable candidate for treatment with one of the following: eribulin, vinorelbine, or capecitabine as per judgement of treating investigator
  • Patient has liver dominant metastatic disease. Liver-dominant is defined as the majority of total tumor burden is located in the liver, and/or the lifethreatening component of the disease is located in the liver
  • MBC metastases must involve ≤ 50% of the liver parenchyma
What rules you out
  • Prior chemoembolization or radioembolization to the liver or prior hepatic arterial infusion therapy.
  • Patient is a WOCBP (i.e., fertile meaning not permanently sterilized and having had a menstrual period within the past 12 months) who is unable to undergo hormonal suppression to avoid menstruation during treatment.
  • Patient requires chronic use of immunosuppressive drugs. NOTE: Oral prednisolone ≤ 10 mg/day or equivalent is allowed.
  • Patient is unable to be temporarily removed from chronic anti-coagulation therapy.
  • Patient has active bacterial infections with systemic manifestations (malaise, fever, leukocytosis).
  • Patient has an active infection, including Hepatitis B and Hepatitis C infection. NOTE: Patients with anti-hepatitis B core antibody (HBc) positive, or hepatitis B surface antigen (HBsAg) but DNA negative are allowed exception(s).
  • Patient has known severe allergic reaction to iodine contrast that cannot be controlled by premedication with antihistamines and steroids.
  • Patient has a history of or known hypersensitivity to melphalan or the components of the Melphalan/HDS system.
  • Patient has known latex allergy.
  • Patient has a history of known hypersensitivity to heparin or the presence of heparininduced thrombocytopenia.
  • Patient has an uncontrolled endocrine disorder including diabetes mellitus, hypothyroidism, or hyperthyroidism.
  • Patient has evidence of clinically significant portal hypertension by history, endoscopy, or radiologic studies (large abdominal varices, prior history of varices by endoscopy).
  • Patient received anti-cancer therapy including radiotherapy or investigational agent for any indication ≤ 30 days prior to randomization.
  • Patients should have recovered to Grade 1 or less for AEs related to prior treatment unless deemed clinically not significant, such as lymphopenia, anemia, or grade 2 neuropathy due to prior taxane treatment. NOTE: Certain side effects that are unlikely to develop into serious or life–threatening events (e.g., alopecia) are allowed at ≥ Grade 1.
  • Patient is < 28 days after surgery and surgical wound is not fully healed.
  • Patient is currently under treatment for cancer other than MBC or is not deemed to be cancer free.
  • Patient is not eligible to receive either eribulin or vinorelbine or capecitabine.
  • Albumin level < 3.0 g/dL.
  • Patient has been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  • Patient has New York Heart Association functional classification II, III or IV or active cardiac condition(s), including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), worsening or new-onset congestive heart failure, significant arrhythmias, or severe valvular disease that create(s) undue risks of undergoing general anesthesia.
  • Patient has history or evidence of clinically significant pulmonary disease that precludes the use of general anesthesia.
  • Patient has a history of bleeding disorders, presence of brain metastases or other intracranial abnormalities that would put them at risk for bleeding with anti-coagulation.
  • Patient has known varices at risk of bleeding, including medium or large esophageal or gastric varices, active peptic ulcer, or history of recent hemoptysis.
  • Patient has an active second malignancy or has a history of recent definitively treated invasive cancer within 2 years prior to enrolment. Exceptions are optimally treated and controlled basal cell carcinoma, other skin cancers, thyroid cancer.
  • Patients with symptoms and signs indicating clinically significant progression of disease including cord compression, increasing pain symptoms, increasing oxygen requirements, impending pathological fracture, compressive lymphadenopathy, or symptomatic pleural effusion.
  • Patient is pregnant or breastfeeding.

The study team makes the final eligibility decision.

Where it's taking place

  • United Kingdom
  • United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include United Kingdom; United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

ObesityType 2 diabetesType 1 diabetesPrediabetesWeight lossMetabolic syndromeHigh cholesterolHigh triglyceridesHigh blood pressurePCOSHypothyroidismThyroid diseaseGoutFatty liver disease (NAFLD/NASH)Heart failureCoronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.